Skylands Capital LLC Purchases 29,350 Shares of Haemonetics Corporation $HAE

Skylands Capital LLC boosted its position in Haemonetics Corporation (NYSE:HAE) by 80.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,825 shares of the medical instruments supplier’s stock after purchasing an additional 29,350 shares during the period. Skylands Capital LLC’s holdings in Haemonetics were worth $3,710,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of HAE. Central Pacific Bank Trust Division lifted its holdings in Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock valued at $713,000 after purchasing an additional 188 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Haemonetics by 9.0% during the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares in the last quarter. UMB Bank n.a. increased its stake in Haemonetics by 110.9% in the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 306 shares during the last quarter. Cardinal Capital Management increased its stake in Haemonetics by 1.5% in the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after acquiring an additional 321 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Haemonetics during the 4th quarter worth approximately $26,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Trading Down 0.4%

Shares of HAE opened at $77.34 on Friday. The company’s fifty day simple moving average is $65.41 and its 200-day simple moving average is $66.87. The company has a market cap of $3.51 billion, a P/E ratio of 38.29, a P/E/G ratio of 1.56 and a beta of 0.56. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the firm posted $1.24 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts expect that Haemonetics Corporation will post 5.22 EPS for the current year.

Analyst Ratings Changes

HAE has been the topic of a number of recent research reports. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Citigroup increased their price target on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Mizuho lifted their price target on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $78.33.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.